Increased alpha 2-adrenergic binding sites and antilipolytic effect in adipocytes from genetically obese rats.
We have recently shown that functional alpha 2-adrenergic receptors, assessed by the alpha 2-agonist UK 14304, are present in rat white fat cells as in adipocytes of humans and other species. The aim of the present study was to further characterize rat fat cell alpha 2-adrenoceptors and to examine whether their number and biological effect were altered in fat cells from genetically obese Zucker rats. The maximal antilipolytic effect of UK 14304 was higher in obese than in lean littermates. Epinephrine, when its beta-component was blocked by propranolol, also induced an antilipolytic response that was higher in the obese rats. Similarly, 3H-labeled UK 14304 binding on adipocyte membranes was higher in obese than in lean animals. The radiolabeled alpha 2-antagonist [3H]idazoxan also recognized a higher number of sites in obese animals. However, epinephrine only partially competed for the 3H-labeled UK 14304 and [3H]idazoxan, suggesting that these imidazolinic radioligands labeled not only alpha 2-adrenoceptors but also nonadrenergic binding sites. By contrast, 3H-labeled RX 821002, an alpha 2-antagonist derived from the idazoxan family, did not recognize these sites and allowed accurate quantification of adipocyte alpha 2-adrenoceptors. The number of alpha 2-sites was higher in obese than in lean littermates (Bmax = 64 +/- 5 vs 39 +/- 2 fmol/mg protein, P less than 0.01) without change in affinity. The adipocyte alpha 2-adrenergic responsiveness showed a strong dependency on age and fattening between 5 and 10 weeks of age in both genotypes.(ABSTRACT TRUNCATED AT 250 WORDS)
Carpéné
C
C
INSERM U 317, Toulouse, France.
Rebourcet
M C
MC
Guichard
C
C
Lafontan
M
M
Lavau
M
M
D000273:Adipose Tissue / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D001665:Binding Sites; D000068438:Brimonidine Tartrate; D004146:Dioxanes / Q000378:metabolism; D004837:Epinephrine / Q000494:pharmacology; D019329:Idazoxan / Q000031:analogs & derivatives; D007700:Kinetics; D008066:Lipolysis / Q000187:drug effects; D008297:Male; D009765:Obesity / Q000235:genetics / Q000378:metabolism*; D011433:Propranolol / Q000494:pharmacology; D011810:Quinoxalines / Q000378:metabolism / Q000494:pharmacology; D051381:Rats; D011924:Rats, Zucker; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000378:metabolism*
D004146:Dioxanes; D011810:Quinoxalines; D011942:Receptors, Adrenergic, alpha; D000068438:Brimonidine Tartrate; D011433:Propranolol; C058525:2-methoxyidazoxan; D019329:Idazoxan; D004837:Epinephrine